Ribavirin (5g)
R639,00
Ribavirin: Investigating Its Potential in Cancer Therapy
Ribavirin is a synthetic guanosine analog traditionally used as a broad-spectrum antiviral agent, notably in the treatment of hepatitis C and respiratory syncytial virus (RSV) infections. Beyond its antiviral applications, ribavirin has garnered interest in oncology for its potential anticancer properties.
Mechanisms of Action in Cancer:
- Inhibition of eIF4E: Ribavirin targets the eukaryotic translation initiation factor eIF4E, an oncogene overexpressed in various cancers. By inhibiting eIF4E, ribavirin disrupts the translation of mRNAs essential for tumor growth and survival.
- Induction of Apoptosis: Studies have shown that ribavirin can induce apoptosis (programmed cell death) in cancer cells, contributing to its potential as an anticancer agent.
Clinical Research and Applications:
- Acute Myeloid Leukemia (AML): Clinical trials have explored ribavirin’s efficacy in AML patients, demonstrating clinical benefits by targeting eIF4E.
- Combination Therapies: Ribavirin has been studied in combination with other agents, such as interferon-α, showing enhanced anti-tumor effects in renal carcinoma cells.
Guidelines for Use in Cancer:
- Clinical Supervision: The use of ribavirin in cancer treatment is experimental and should only be undertaken under the guidance of an oncologist within a clinical trial setting.
- Dosage and Administration: Specific dosing regimens for ribavirin in oncology are not well-established and vary across studies. For antiviral treatments, ribavirin is typically administered orally, with dosages adjusted based on body weight and renal function.
- Side Effects: Common side effects include anemia, fatigue, and gastrointestinal disturbances. Due to its potential to cause hemolytic anemia, patients require regular monitoring of hemoglobin levels.
Disclaimer:
This information is for educational purposes only and should not be considered medical advice. Ribavirin is not approved for cancer treatment outside of clinical trials. Always consult with a qualified healthcare professional before considering any experimental treatments.
Out of stock
Ribavirin Dosage for Cancer Research
Ribavirin’s dosage for cancer is not standardized and varies based on the study design, cancer type, and whether it is used as a monotherapy or in combination with other treatments. Below are general guidelines derived from research and clinical trials:
Typical Dosage in Clinical Studies
- Acute Myeloid Leukemia (AML):
- Dose: 1,000–1,200 mg per day (oral administration) adjusted based on body weight.
- Duration: Administered daily in cycles, depending on patient response and tolerability.
- Combination Therapy with Interferon-α:
- Dose: Ranges from 400–600 mg twice daily (oral), combined with interferon injections.
- Purpose: Enhances anti-tumor effects in cancers such as renal cell carcinoma and hepatocellular carcinoma.
Guidance for Use
- Administration:
- Ribavirin is typically taken orally in tablet or capsule form.
- It should be consumed with food to minimize gastrointestinal side effects.
- Adjustments:
- Dosages may need adjustment for patients with renal or hepatic impairment.
- Regular monitoring of hemoglobin levels is crucial to prevent severe anemia, a known side effect of ribavirin.
- Duration of Therapy:
- Duration is variable, often based on the type of cancer, response to treatment, and tolerance to the drug.
- Continuous cycles with intermittent monitoring are commonly implemented in clinical settings.
Important Notes
- Monitoring: Ribavirin can cause hemolytic anemia, requiring frequent blood tests to monitor hemoglobin and red blood cell levels.
- Side Effects: Other common side effects include fatigue, nausea, rash, and gastrointestinal discomfort.
- Contraindications: Ribavirin is not recommended for pregnant women or individuals with severe heart disease due to the risk of severe anemia.
Disclaimer
The above dosage information is based on clinical studies and experimental research. Ribavirin is not currently approved for cancer treatment outside of research settings. Its use should only occur under the guidance of an oncologist or within a clinical trial. Self-administration without medical supervision can lead to serious side effects or complications. Always consult with a qualified healthcare provider before considering experimental therapies.
